Skip to main content

Early Posaconazole Step-Down After 1 Week of Initial Combination Therapy Versus 4-Week Liposomal Amphotericin B Monotherapy for Pulmonary Mucormycosis: An Open-Label Randomized Trial

In brief

Early posaconazole step-down showed 53% success, versus 47% with amphotericin

In an exploratory randomized trial of 72 adults with diabetes and pulmonary mucormycosis, switching to oral posaconazole after one week of combination treatment produced six-week success in 53%, compared with 47% after four weeks of intravenous amphotericin. The difference was uncertain, and mortality estimates also favored step-down; a larger multicenter trial is needed to establish whether the shorter intravenous course is safe and effective.

Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (Q1)
Published
18 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Akshay Raut, Avadh Vithlani, Ritesh Agarwal, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Sahajal Dhooria, et al.
PMID
43051529
DOI
10.1016/j.cmi.2026.11.012

Why clinicians should know about it

Abstract

OBJECTIVES: Liposomal amphotericin B (LAMB) is recommended as first-line therapy for pulmonary mucormycosis (PM). However, the optimal duration of intravenous LAMB before transition to oral step-down therapy is uncertain. We evaluated an early step-down strategy of oral posaconazole in an exploratory randomized trial. METHODS: In this investigator-initiated, open-label, exploratory randomized trial conducted at a tertiary center, adults with suspected PM were randomized pending diagnostic confirmation. The prespecified modified intention-to-treat (mITT) population included participants with proven/probable PM confirmed within 4 working days of randomization. Participants received either LAMB 5 mg/kg/day for four weeks (4-week LAMB arm) or LAMB plus oral posaconazole (delayed-release tablets) for one week followed by 3 weeks of posaconazole alone (early-step-down arm). Maintenance posaconazole was planned thereafter in both groups. The primary outcome was treatment success at six weeks (complete/partial clinico-radiologic response), assessed by a multidisciplinary panel. Secondary outcomes included 12-week treatment success, 90-day mortality, and treatment-emergent adverse events. Risk differences (RDs) are reported as early-step-down minus 4-week LAMB. RESULTS: Of the 82 randomized participants, 72 comprised the mITT population (4-week LAMB, n=34; early-step-down, n=38). All participants had diabetes mellitus. At six weeks, treatment success occurred in 20/38 (52.6%) participants in the early-step-down arm and 16/34 (47.1%) in the 4-week LAMB group (RD, 5.6% [95% CI, -20.3% to 31.5%]). Twelve-week treatment success was 62.2% vs. 47·1% (RD, 15.1% [95% CI, -10.6% to 40.9%]), and 90-day mortality was 35.1% vs. 44·1% (RD, -9% [95% CI, -34.5% to 16.5%]) with the early-step-down and 4-week LAMB arms, respectively. Thrombophlebitis occurred in 26.3% versus 50.0% (RD, -23.7% [95% CI, -48.3% to 1.0%]). CONCLUSIONS: In this exploratory trial of diabetes-associated PM, early posaconazole step-down after 1 week of combination therapy showed numerically higher treatment success, but estimates were imprecise and compatible with meaningful benefit or harm. A larger multicenter trial is warranted. TRIAL REGISTRATION: clinicaltrials.gov: NCT05468372.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.